Referred to the House Committee on Energy and Commerce.
The BRAIN Act directs NIH and HHS to improve brain tumor research, patient access, and survivorship care. It requires reporting of NIH-funded brain tumor biospecimen collections into a searchable database and creates competitive research programs: a $50M/year Glioblastoma Therapeutics Network, $10M/year CAR–T team awards, $10M total for a national clinical trials and biomarker awareness campaign, and $5M/year pilot survivor-care programs.
Support for targeted research funding versus worry about new federal spending
Relative to its intended legislative type, this bill is a structured substantive authorization that adds multiple statutory programs, authorizes funding, and assigns clear agency responsibilities.
The BRAIN Act directs NIH and HHS to improve brain tumor research, patient access, and survivorship care.
It requires reporting of NIH-funded brain tumor biospecimen collections into a searchable database and creates competitive research programs: a $50M/year Glioblastoma Therapeutics Network, $10M/year CAR–T team awards, $10M total for a national clinical trials and biomarker awareness campaign, and $5M/year pilot survivor-care programs.
The bill also mandates FDA guidance within one year to reduce exclusion of brain tumor patients from clinical trials.
Low‑ideology, targeted health‑research bill with modest costs improves prospects, but requires committee approval, appropriations, and some institutional pushback on reporting rules.
Relative to its intended legislative type, this bill is a structured substantive authorization that adds multiple statutory programs, authorizes funding, and assigns clear agency responsibilities. It presents a clear problem statement and reasonable implementation assignments, but several operational details, safeguards, and performance-accountability mechanisms remain high-level or permissive.
Support for targeted research funding versus worry about new federal spending
These are examples from the analysis, not a ranked list of the most-affected groups.
Support for targeted research funding versus worry about new federal spending
Generally strongly supportive; advances research, equity, and patient-centered survivorship care.
Sees mandated biospecimen transparency, outreach to underserved populations, and funding for CAR–T and glioblastoma research as important steps.
Generally supportive but pragmatic; favors the bill's targeted research and awareness goals while wanting clear accountability, measurable outcomes, and limited administrative burden.
Accepts modest appropriations if matched with oversight and peer review.
Cautiously mixed to somewhat opposed; supports medical research but worries about new federal mandates, reporting burdens, and additional spending.
Concerned about NIH enforcement power and potential data or regulatory overreach.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Low‑ideology, targeted health‑research bill with modest costs improves prospects, but requires committee approval, appropriations, and some institutional pushback on reporting rules.
The bill has not accumulated any surfaced votes yet.
Support for targeted research funding versus worry about new federal spending
Low‑ideology, targeted health‑research bill with modest costs improves prospects, but requires committee approval, appropriations, and some…
Relative to its intended legislative type, this bill is a structured substantive authorization that adds multiple statutory programs, authorizes funding, and assigns clear agency responsibilities. It presents a clear pr…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.